

Methods: A comprehensive literature review was conducted, focusing on studies from 2000 to 2023 sourced from PubMed, MEDLINE, and Cochrane Library. Search terms included “postictal delirium,” “Electroconvulsive Therapy,” “post-anesthesia delirium,” and “peri-operative cognitive disorders.” Key variables analyzed included onset, duration, cognitive and behavioral symptoms, associated risk factors, and treatment protocols for both conditions.

Results: The analysis revealed key differences between PD and PAD. PD generally presents immediately after ECT and resolves within minutes to hours, whereas PAD has variable onset, occurring immediately after surgery or several days later, with symptoms lasting hours to days. Cognitive symptoms also differ. PD is characterized by brief confusion and both anterograde and retrograde amnesia, while PAD presents with prolonged confusion, disorientation, and short-term memory impairment. Behaviorally, PD often involves repetitive, patterned, involuntary movements (stereotypies), such as hand flapping and rocking, whereas PAD is characterized by non-patterned agitation, including both voluntary and involuntary movements. PD typically includes fatigue and altered consciousness, while PAD may present with hallucinations, delusions, and significant sleep disturbances. Risk factors for these syndromes also vary. PD is linked to the intensity of the ECT stimulus and pre-existing neurological conditions, while PAD is influenced by factors such as patient age, type of surgery, anesthesia duration, and baseline cognitive status.

Conclusions: PD and PAD share clinical overlap, particularly in cognitive symptoms, but they differ in onset, duration, behavioral patterns, and associated risk factors. PD following ECT is typically brief and marked by stereotyped movements, while PAD presents with prolonged confusion and non-patterned agitation. Accurate differentiation between these conditions is crucial for appropriate diagnosis and management in the PACU setting. Further research is needed to uncover the underlying mechanisms and enhance therapeutic strategies for these syndromes.

Disclosure of Interest: None Declared

EPP690

Effect of intermittent theta-burst stimulation on chronobiological hypothalamic-pituitary-thyroid axis activity in resistant depressed patients

F. Duval^{1*}, M.-C. Mokrani¹, V. Danila¹, T. Weiss¹, F. Gonzalez Lopera¹ and M. I. Tomsa¹

¹Psychiatry, Centre Hospitalier, Rouffach, France

*Corresponding author.

doi: 10.1192/j.eurpsy.2025.888

Introduction: So far, the effects of intermittent theta-burst stimulation (iTBS) treatment—a form of repetitive transcranial magnetic stimulation (rTMS) technique—on the hypothalamic-pituitary-thyroid (HPT) axis activity are poorly understood. In depression, and especially in treatment resistant depressed patients (TRDs), this axis is often dysregulated. We have previously demonstrated that the difference between the 23:00 h and 08:00 h thyrotropin (TSH) response to protirelin (TRH) tests on the same day ($\Delta\Delta$ TSH test) is a very sensitive chronobiological index since it is reduced in about three quarters of major depressed inpatients.

Objectives: The present study aimed at assessing the effects of iTBS treatment applied to the left dorsolateral prefrontal cortex (LDPFC) in hospitalized TRDs (defined as having at least 2 treatment failures) with abnormal chronobiological HPT functioning at baseline (BL).

Methods: The $\Delta\Delta$ TSH test was performed in 18 TRDs and 18 matched healthy hospitalized control subjects (HCs). To be enrolled in this study, patients had to show at BL reduced $\Delta\Delta$ TSH values (i.e., < 2.5 mU/L) and a score of 18 or greater on the 17-item Hamilton Rating Scale for Depression (HAMD-17). All included TRDs were treated with antidepressants at the time of hospital admission. Drug dosages remained unchanged over the past month and kept stable throughout the course of iTBS. The $\Delta\Delta$ TSH test was repeated in all inpatients after 20 iTBS sessions (single daily session for 5 days of the week). Clinical response was defined as a reduction in HAMD-17 total score $> 50\%$ from BL and a final HAMD-17 score ≤ 8 .

Results: Compared to HCs, $\Delta\Delta$ TSH values were lower in TRDs at BL ($p < 0.00001$ by U test). After 20 iTBS sessions, HAM-D scores decreased ($p = 0.001$ by T-test) and $\Delta\Delta$ TSH values increased ($p = 0.01$ by T-test) compared to BL, although endpoint $\Delta\Delta$ TSH values remained lower than those of HCs ($p = 0.02$ by T-test). However, there was a relationship between the reduction in HAM-D scores from BL to endpoint and the increase in $\Delta\Delta$ TSH values ($\rho = -0.54$; $n = 18$; $p = 0.02$). At endpoint, 10 patients (55%) showed $\Delta\Delta$ TSH normalization (among them 8 [80%] were responders), while 8 patients (45%) did not normalize their $\Delta\Delta$ TSH (all were non-remitters) ($p = 0.001$ by Fisher Exact test).

Conclusions: Although the underlying mechanisms remain to be elucidated, the results of our present pilot study in TRDs suggest that successful iTBS treatment can restore a normal chronobiological activity of the HPT axis and vice versa.

Disclosure of Interest: None Declared

EPP693

ECT in Huntington's Psychosis - an unexplored therapeutic option

N. Ramalho^{1*}, T. Rocha¹, J. F. Cunha¹, J. C. Moura¹, J. Leal¹, D. Seabra¹, I. Lopes¹, G. Santos¹, M. Rosa¹ and A. Garcia¹

¹Psychiatric and Mental Health Department, ULSAR, Barreiro, Portugal

*Corresponding author.

doi: 10.1192/j.eurpsy.2025.889

Introduction: Huntington's disease (HD) is a progressive neurodegenerative disorder characterized by motor dysfunction, cognitive decline, and psychiatric symptoms. Among these psychiatric manifestations, psychosis occurs in a subset of patients, presenting significant challenges for both diagnosis and treatment. While pharmacological interventions, such as antipsychotics, are commonly used to manage psychosis in HD, they often come with limited efficacy and a high risk of adverse effects. Electroconvulsive therapy (ECT), traditionally employed in the treatment of severe mood disorders and treatment-resistant psychosis, has garnered minimal attention as a therapeutic option for psychosis associated with HD. This is proven by the absence of literature focusing specifically on the use of ECT for treatment of Huntington's Psychosis. This underexplored avenue holds potential, given ECT's neuroplastic and neurochemical effects, which may counteract the neurodegenerative processes seen in HD. Exploring the efficacy of ECT in HD-associated psychosis could not only provide symptom relief but also offer insights into the broader neuropsychiatric management of the disease.

Objectives: This review aims to highlight the therapeutic potential of ECT as a novel intervention in Huntington's psychosis, addressing the current gap in clinical research and therapeutic strategies.